Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults with Asthma

Trial Identifier: D8210C00005
Sponsor: AstraZeneca
Start Date: August 2024
Primary Completion Date: October 2025
Study Completion Date: October 2025
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Calgary, AB, CA, T2N 4Z6
CA, BC Vancouver, BC, CA, V5Z 1M9
CA, QC Montréal, QC, CA, H4A 3J1
CA, QC Quebec, QC, CA, G1V 4G5
DE Frankfurt, DE, 60596
DE Grosshansdorf, DE, 22927
DK København NV, DK, 2400
ES Barcelona, ES, 8025
ES Palma de Mallorca, ES, 07010
ES Santander, ES, 39008
GB Birmingham, GB, B9 5SS
GB Glasgow, GB, G12 0YN
GB Headington, GB, OX3 9DU
GB Leicester, GB, LE3 9QP
GB Liverpool, GB, L7 8YE
GB London, GB, W12 0HS
GB Manchester, GB, M23 9QZ
GB Southampton, GB, SO9 4XY